When combined with FISH tests and IHC screenings, it has been shown that advanced-stage NSCLC patients who demonstrate ALK gene rearrangements will typically respond well to ALK tyrosine kinase inhibitor therapy. Here, ALK is linked to non-small cell lung carcinoma.